---
title: "Sangamo Therapeutics reveals detailed data from registrational STAAR study on Fabry Disease at WORLDSymposium 2026."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274713477.md"
description: "Sangamo Therapeutics recently unveiled in-depth information from the registrational STAAR study on Fabry disease at the World Symposium in 2026. The study has provided crucial insights into the disease, covering key aspects and significant findings regarding treatment. Fabry disease impacts a substantial number of individuals globally, making the findings presented by Sangamo Therapeutics significant for the medical community. This presentation at the World Symposium underlines the importance of the research conducted by the company and sheds light on potential advancements in addressing Fabry disease."
datetime: "2026-02-03T21:07:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274713477.md)
  - [en](https://longbridge.com/en/news/274713477.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274713477.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274713477.md) | [繁體中文](https://longbridge.com/zh-HK/news/274713477.md)


# Sangamo Therapeutics reveals detailed data from registrational STAAR study on Fabry Disease at WORLDSymposium 2026.

Sangamo Therapeutics recently unveiled in-depth information from the registrational STAAR study on Fabry disease at the World Symposium in 2026. The study has provided crucial insights into the disease, covering key aspects and significant findings regarding treatment. Fabry disease impacts a substantial number of individuals globally, making the findings presented by Sangamo Therapeutics significant for the medical community. This presentation at the World Symposium underlines the importance of the research conducted by the company and sheds light on potential advancements in addressing Fabry disease.

### Related Stocks

- [Sangamo Therapeutics, Inc. (SGMO.US)](https://longbridge.com/en/quote/SGMO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md)
- [Craig-Hallum Sticks to Their Buy Rating for Apogee Therapeutics (APGE)](https://longbridge.com/en/news/277492684.md)
- [Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | IRD Stock News](https://longbridge.com/en/news/277220357.md)
- [Rallybio to acquire Candid Therapeutics](https://longbridge.com/en/news/277617458.md)
- [FDA official says UniQure fell short on Huntington's trial, defends new study request](https://longbridge.com/en/news/277874344.md)